API | dinaciclib

dinaciclib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications. ^Wikipedia

Chemistry

SMILES: CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N4CCCC[C@H]4CCO
InChIKey: PIMQWRZWLQKKBJ-SFHVURJKSA-N
Mol. Mass: 396.5
ALogP: 2.28 Partition coefficient
ChEMBL Molecule:
dinaciclib

More Chemistry

Pharmacology

Mechanisms of Action:
- Cyclin-dependent kinase 1 (Homo sapiens) ^UniProt
- Cyclin-dependent kinase 2 (Homo sapiens) ^UniProt
- Cyclin-dependent-like kinase 5 (Homo sapiens) ^UniProt
- Cyclin-dependent kinase 9 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

dinaciclib | mk-7965 | sch727965 | sch 727965 | sch-727965

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Prolymphocytic (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue